Olanzapine is indicated for the treatment of schizophrenia and can be effective in maintaining the clinical improvement during continuation therapy in patients who have shown an initial treatment response. Olanzapine is indicated for the treatment of moderate to severe manic episode.
Olanzapine is not recommended for use in children and adolescents below 18 years of age due to a lack of data on safety and efficacy. In patients whose manic episode has responded to olanzapine treatment, olanzapine is indicated for the prevention of recurrence in patients with bipolar disorder. The product is sold in Bulgaria.